Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04961619 | Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.(LEAD Melanoma) | completed | — | 39 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 12, 2025 | clinicaltrials |
| NCT01950390 | Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 169 | National Cancer Institute (NCI)NIH | 1 |
| Dec 11, 2025 |
| clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05675709 | Enhancing Skin Cancer Early Detection and Treatment in Primary Care | completed | N/A | 54 | OHSU Knight Cancer InstituteOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05383170 | A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers(Catalyst) | completed | Phase 1 / Phase 2 | 6 | Cytovation ASINDUSTRY | 5 | Nov 28, 2025 | clinicaltrials |
| NCT04570332 | BO-112 With Pembrolizumab in Unresectable Malignant Melanoma(SPOTLIGHT203) | completed | Phase 2 | 42 | Highlight TherapeuticsINDUSTRY | 2 | Nov 26, 2025 | clinicaltrials |
| NCT02639026 | Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers | completed | Phase 1 | 53 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT01334008 | Study of Circulating Tumoral DNA in Metastatic Choroidal Melanoma | completed | N/A | 40 | Institut CurieOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05668585 | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | completed | Phase 1 | 89 | C4 Therapeutics, Inc.INDUSTRY | 5 | Nov 21, 2025 | clinicaltrials |
| NCT02854124 | Tracing Dissemination of Melanoma Cells in Healthy Tissues(DISSEMELA) | completed | — | 226 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04705168 | Study of the Nevisense Device to Assess Atypical Skin Lesions | completed | — | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT01558349 | Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques | completed | — | 73 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT01473004 | SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver | completed | Phase 2 | 48 | Thomas Jefferson UniversityOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT07091695 | Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab | completed | — | 100 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 12, 2025 | clinicaltrials |
| NCT01397708 | Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma | completed | Phase 1 / Phase 2 | 26 | Alaunos TherapeuticsINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT04566302 | Pilot Study of Imaging Human Skin With High-Speed Spectrally Encoded Confocal Microscopy | completed | N/A | 16 | Massachusetts General HospitalOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT04700072 | Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) | completed | Phase 1 / Phase 2 | 56 | Merck Sharp & Dohme LLCINDUSTRY | 8 | Oct 28, 2025 | clinicaltrials |
| NCT04208958 | Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer(ConsortiumIO) | completed | Phase 1 / Phase 2 | 56 | Vedanta Biosciences, Inc.INDUSTRY | 1 | Oct 27, 2025 | clinicaltrials |
| NCT05091346 | A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 89 | Eisai Inc.INDUSTRY | 4 | Oct 24, 2025 | clinicaltrials |
| NCT00244816 | Taxoprexin® Treatment for Advanced Eye Melanoma | completed | Phase 2 | 22 | American Regent, Inc.INDUSTRY | 1 | Oct 23, 2025 | clinicaltrials |
| NCT05293496 | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors | completed | Phase 1 | 31 | MacroGenicsINDUSTRY | 1 | Oct 14, 2025 | clinicaltrials |
| NCT06180460 | CALM: Managing Distress in Malignant Brain Cancer | completed | N/A | 60 | Virginia Commonwealth UniversityOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT00249262 | Taxoprexin Treatment for Advanced Skin Melanoma | completed | Phase 2 | 30 | American Regent, Inc.INDUSTRY | 0 | Sep 26, 2025 | clinicaltrials |
| NCT04812470 | Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases(HAITILS) | completed | Phase 1 | 8 | Vastra Gotaland RegionOTHER_GOV | 1 | Sep 22, 2025 | clinicaltrials |
| NCT02849145 | Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)(ctDNA R0) | completed | N/A | 60 | Institut CurieOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04118062 | Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR) | completed | N/A | 128 | Institut CurieOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04577807 | LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma | completed | Phase 2 | 27 | Istari Oncology, Inc.INDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT01753089 | Dendritic Cell Activating Scaffold in Melanoma | completed | Phase 1 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT02626065 | Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies(PAIR) | completed | Phase 4 | 32 | Hospices Civils de LyonOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT02831634 | A Feasibility Study to Identify T-cell Responses to Neo-epitopes in Tumor Invaded Lymph Nodes (NeoEpitope)(NeoEpitope) | completed | N/A | 25 | Institut CurieOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT04728113 | Early Integration of Supportive Care for Metastatic Uveal Melanoma Patients (EarlyTogether)(EARLY TOGETHER) | completed | N/A | 162 | Institut CurieOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT03715205 | Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) | completed | Phase 4 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT04772989 | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies(ARC-12) | completed | Phase 1 | 94 | Arcus Biosciences, Inc.INDUSTRY | 3 | Aug 28, 2025 | clinicaltrials |
| NCT04988841 | Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma(PICASSO) | completed | Phase 2 | 70 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT05819255 | TRAQinform Assessment of Immunotherapy Response(AIQ TRAQinform) | completed | — | 26 | AIQ SolutionsINDUSTRY | 1 | Aug 28, 2025 | clinicaltrials |
| NCT05578872 | A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). | completed | Phase 1 / Phase 2 | 29 | Anaveon AGINDUSTRY | 5 | Aug 26, 2025 | clinicaltrials |
| NCT02752074 | A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301) | completed | Phase 3 | 706 | Incyte CorporationINDUSTRY | 23 | Aug 24, 2025 | clinicaltrials |
| NCT03708328 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 134 | Hoffmann-La RocheINDUSTRY | 6 | Aug 20, 2025 | clinicaltrials |
| NCT05259696 | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)(GLIMMER-01) | completed | Phase 1 / Phase 2 | 69 | Palleon Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT02652455 | Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma | completed | Early Phase 1 | 11 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT05004025 | Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma | completed | Phase 1 | 10 | HonorHealth Research InstituteOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT02327078 | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) | completed | Phase 1 / Phase 2 | 307 | Incyte CorporationINDUSTRY | 2 | Aug 14, 2025 | clinicaltrials |
| NCT01863108 | Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma(GeniusVac-Mel4) | completed | Phase 1 | 9 | University Hospital, GrenobleOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT02475213 | Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer | completed | Phase 1 | 146 | MacroGenicsINDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT03964298 | Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma(imMUno) | completed | — | 100 | Institut CurieOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT02874040 | Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser) | completed | N/A | 87 | Institut CurieOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT02681549 | Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 41 | Yale UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT04217473 | TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma(TUNINTIL) | completed | Phase 1 | 17 | TILT Biotherapeutics Ltd.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT04368247 | Skin Fluorescent Imaging (SFI) System in Patients With Nevi | completed | — | 300 | Orlucent, IncINDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 12, 2025source: clinicaltrials